How might the results of LEADER impact the prioritization of GLP-1 RAs as foundational agents for T2D, either alone or in combination with SGLT2 inhibitors or long-acting basal insulin?

How might the results of LEADER impact the prioritization of GLP-1 RAs as foundational agents for T2D, either alone or in combination with SGLT2 inhibitors or long-acting basal insulin?

How might the results of LEADER impact the prioritization of GLP-1 RAs as foundational agents for T2D, either as stand-alone agents or in combination with SGLT2 inhibitors? Or with long-acting basal insulin?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Ralph DeFronzo, MD

Ralph DeFronzo, MD

Professor of Medicine
Chief of the Diabetes Division
The University of Texas Health Science Center at San Antonio
San Antonio, Texas